- Home
- NSTS vs MIRA Comparison
NSTS vs MIRA Comparison
Compare NSTS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | MIRA |
|---|---|---|
| Founded | 1921 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 53.2M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NSTS | MIRA |
|---|---|---|
| Price | $12.00 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.6K | ★ 124.8K |
| Earning Date | 03-27-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $256,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $0.81 |
| 52 Week High | $13.06 | $2.45 |
Technical Indicators
Market Signals| Indicator | NSTS | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.21 | 28.75 |
| Support Level | $11.85 | N/A |
| Resistance Level | $12.30 | $1.35 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 0.00 | 6.45 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.